https://www.biospace.com/drug-development/syros-crashes-over-90-on-late-stage-mds-fail-loan-default
Another failed myelodysplastic syndrome trial.
https://www.biospace.com/fda-approves-geron-s-first-in-class-telomerase-inhibitor-for-blood-disorder
This was approved for myelodysplastic syndrome back in June
Rytelo is approved for myelodysplastic syndromes (MDS) patients with transfusion-dependent anemia who do not respond or are ineligible for the standard-of-care treatment, erythropoiesis-stimulating agents (ESA)
Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales
"These results also reflect the high unmet need in lower-risk MDS and the compelling value proposition of RYTELO"
Here's a list of Imetelstat's possible side effects.
Low White Blood Cell Count (Leukopenia or Neutropenia)
Low Platelet Count (Thrombocytopenia)
Liver ToxicityFatigue
Joint or Muscle Pain
Less common, but important side effects can include: Reproductive Concerns
SNT- 5055 No side effects
Geron has a similar pipeline to us, looking at MDS and MF. In my opinion our pipeline is a lot more attractive though when you add on scar treatment and organ fibrosis in cancer.
Geron market cap $2.33 billion US.
Back in August 2023, BMS got a label extension for Reblozyl. It was first approved in 2020 but only in patients who had failed to respond to an erythropoiesis-stimulating agent (ESA), the historically front-line treatment.
FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
GlobalData analysts project Reblozyl sales to reach $3.2 billion by 2029, while BMS has set its sights on $4 billion-plus aspirations for the drug.
BMS had $12.47 billion Aus cash on hand in September. Another possible suitor who I'd suggest is keeping a very close eye on us.
https://www.biospace.com/drug-development/syros-crashes-over-90-o...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| SNT (ASX) Chart |
Day chart unavailable